Ygalo Continues to Show Positive Results in RRMM Patients, Oncopeptides Announces
Combination treatment with Ygalo (melflufen) continues to be safe and effective in difficult-to-treat patients with relapsed or refractory multiple myeloma (RRMM), according to the latest results from clinical trials. Data from the clinical program of Ygalo and multiple myeloma’s impact on quality of life will be presented…